The groundbreaking study identifying a β-arrestin2:Akt:protein phosphatase 2 complex as a target of lithium action in behavior disorders [16] provides compelling evidence that targeting GPCR signaling complexes with drugs is an untapped and fruitful area of drug discovery. Here, AKT1 is linked to Atypical behavior.